Reporter brief
Senolytics To Alleviate Mobility Issues and Neurological Impairment in Aging
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract does not report whether the intervention was actually safe or feasible.
- No efficacy data are provided on cerebral blood flow, mobility, cognition, or Alzheimer's disease progression.
- As a pilot study, any findings would not establish effectiveness in the general population of older adults at AD risk.
Study design and sample
Other; Human.
Older adults at risk of Alzheimer's disease
- Design
- Other
- Sample
- —
- Journal
- Lewis Lipsitz
- Published
- Mar 17, 2025
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.